By co-expressing CXCR5 and CCR6, we engineered HER2-CAR T cells with enhanced homing capacity, specifically addressing the unmet therapeutic need in this refractory NSCLC subgroup. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.